Dyne Therapeutics (NASDAQ:DYN) Sets New 12-Month Low – Should You Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN) hit a new 52-week low during trading on Monday . The stock traded as low as $8.15 and last traded at $8.17, with a volume of 2602714 shares trading hands. The stock had previously closed at $9.42.

Wall Street Analyst Weigh In

DYN has been the topic of several recent analyst reports. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. HC Wainwright reiterated a “buy” rating and issued a $46.00 price target on shares of Dyne Therapeutics in a research note on Monday, March 17th. Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $45.00 target price on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Finally, Scotiabank assumed coverage on Dyne Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $47.46.

Dyne Therapeutics Stock Performance

The firm has a market cap of $869.90 million, a P/E ratio of -2.16 and a beta of 1.21. The company’s 50 day moving average is $12.81 and its 200 day moving average is $22.52.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.04. On average, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insiders Place Their Bets

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the transaction, the insider now owns 199,087 shares in the company, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders have sold 6,237 shares of company stock valued at $77,760. 20.77% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp increased its position in Dyne Therapeutics by 0.3% in the 4th quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company’s stock valued at $5,532,000 after buying an additional 698 shares in the last quarter. Summit Investment Advisors Inc. raised its position in shares of Dyne Therapeutics by 9.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock worth $203,000 after purchasing an additional 721 shares during the period. Quantbot Technologies LP acquired a new position in shares of Dyne Therapeutics during the third quarter worth approximately $34,000. KBC Group NV increased its stake in Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after purchasing an additional 978 shares in the last quarter. Finally, Virtue Capital Management LLC lifted its stake in shares of Dyne Therapeutics by 4.4% in the third quarter. Virtue Capital Management LLC now owns 23,208 shares of the company’s stock valued at $834,000 after buying an additional 981 shares in the last quarter. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.